Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Post by DrHolidayon Jul 10, 2018 11:40am
95 Views
Post# 28293255

NO SALE!

NO SALE!When the market makers start moving the stock up after having accumulated a sizeable position, then the games being played will have to stop. Bullish brokers and buyside analysts will publish recommendations with specific targets.

Manipulation by high frequency traders and shorty will change from sell orders to buys to throw long and cover out of fear of being burned alive on a stock halt and gap up much higher pending great news. The game of manipulation could be by a company trying to buy as much stock as possible as low as possible prior to launching a hostile takeover bid. This strategy is unlikely to succeed as there are a number of potential players and white knights that would be willing to either partner or make a friendly offer that would be acceptable to shareholders of ICO.

For this reason, ICO needs to adopt a PPP poison pill provision to fend off any hostility, and only recommend tendering of shares to any suitor if their offer will be strong.
The best course of action would be for the company to partner with a major pharmaceutical company, so that shareholders can reap the fruits rather than selling out too early for a pittance.


DOC.
<< Previous
Bullboard Posts
Next >>